Industry
Biotechnology
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 12, 2024 | 1:43 pm
Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 11:26 am
Portfolio Pulse from Benzinga Newsdesk
August 06, 2024 | 12:13 pm
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 2:24 pm
Portfolio Pulse from Benzinga Newsdesk
May 06, 2024 | 10:42 am
Portfolio Pulse from Benzinga Newsdesk
May 02, 2024 | 12:06 pm
Portfolio Pulse from Avi Kapoor
April 22, 2024 | 12:32 pm
Portfolio Pulse from Benzinga Newsdesk
April 22, 2024 | 11:21 am
Portfolio Pulse from Benzinga Newsdesk
April 08, 2024 | 11:15 am
Portfolio Pulse from Vandana Singh
April 05, 2024 | 4:57 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.